Anesthesiologie - Urgentiegeneeskunde
  • Home
  • Updates
    • Nieuws
    • Artikel van de week
    • Tip van de week
    • Congres tips & reviews
    • Cursus Tips & Reviews
  • D-examen
  • Online Lectures
    • Resuscitation
    • Trauma
    • Airway Management
    • Prehospital Emergency Medicine
    • Crew Resource Management
    • ResusNL
  • Educatie
    • Apps
    • Podcasts
    • Blogs & Sites
    • Boeken
    • Congressen
    • Cursussen
  • Over ons

Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT). Lancet 2020; 395: 1927–36

8/24/2020

 
The HALT-IT Trial Collaborators*
Summary
Background: Tranexamic acid reduces surgical bleeding and reduces death due to bleeding in patients with trauma. Meta-analyses of small trials show that tranexamic acid might decrease deaths from gastrointestinal bleeding. We aimed to assess the effects of tranexamic acid in patients with gastrointestinal bleeding.
Methods: We did an international, multicentre, randomised, placebo-controlled trial in 164 hospitals in 15 countries. Patients were enrolled if the responsible clinician was uncertain whether to use tranexamic acid, were aged above the minimum age considered an adult in their country (either aged 16 years and older or aged 18 years and older), and had significant (defined as at risk of bleeding to death) upper or lower gastrointestinal bleeding. Patients were randomly assigned by selection of a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients received either a loading dose of 1 g tranexamic acid, which was added to 100 mL infusion bag of 0·9% sodium chloride and infused by slow intravenous injection over 10 min, followed by a maintenance dose of 3 g tranexamic acid added to 1 L of any isotonic intravenous solution and infused at 125 mg/h for 24 h, or placebo (sodium chloride 0·9%). Patients, caregivers, and those assessing outcomes were masked to allocation. The primary outcome was death due to bleeding within 5 days of randomisation; analysis excluded patients who received neither dose of the allocated treatment and those for whom outcome data on death were unavailable. This trial was registered with Current Controlled Trials, ISRCTN11225767, and ClinicalTrials.gov, NCT01658124.
Findings: Between July 4, 2013, and June 21, 2019, we randomly allocated 12 009 patients to receive tranexamic acid (5994, 49·9%) or matching placebo (6015, 50·1%), of whom 11952 (99·5%) received the first dose of the allocated treatment. Death due to bleeding within 5 days of randomisation occurred in 222 (4%) of 5956 patients in the tranexamic acid group and in 226 (4%) of 5981 patients in the placebo group (risk ratio [RR] 0·99, 95% CI 0·82–1·18). Arterial thromboembolic events (myocardial infarction or stroke) were similar in the tranexamic acid group and placebo group (42 [0·7%] of 5952 vs 46 [0·8%] of 5977; 0·92; 0·60 to 1·39). Venous thromboembolic events (deep vein thrombosis or pulmonary embolism) were higher in tranexamic acid group than in the placebo group (48 [0·8%] of 5952 vs 26 [0·4%] of 5977; RR 1·85; 95% CI 1·15 to 2·98).
Interpretation: We found that tranexamic acid did not reduce death from gastrointestinal bleeding. On the basis of our results, tranexamic acid should not be used for the treatment of gastrointestinal bleeding outside the context of a randomised trial.
Link naar het artikel

The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition

4/22/2016

 
Critical Care 2016 20:100   DOI: 10.1186/s13054-016-1265-x   ©  Rossaint et al. 2016

Background: Severe trauma continues to represent a global public health issue and mortality and morbidity in trauma patients remains substantial. A number of initiatives have aimed to provide guidance on the management of trauma patients. This document focuses on the management of major bleeding and coagulopathy following trauma and encourages adaptation of the guiding principles to each local situation and implementation within each institution.

Methods: The pan-European, multidisciplinary Task Force for Advanced Bleeding Care in Trauma was founded in 2004 and included representatives of six relevant European professional societies. The group used a structured, evidence-based consensus approach to address scientific queries that served as the basis for each recommendation and supporting rationale. Expert opinion and current clinical practice were also considered, particularly in areas in which randomised clinical trials have not or cannot be performed. Existing recommendations were reconsidered and revised based on new scientific evidence and observed shifts in clinical practice; new recommendations were formulated to reflect current clinical concerns and areas in which new research data have been generated. This guideline represents the fourth edition of a document first published in 2007 and updated in 2010 and 2013.
​
Results: The guideline now recommends that patients be transferred directly to an appropriate trauma treatment centre and encourages use of a restricted volume replacement strategy during initial resuscitation. Best-practice use of blood products during further resuscitation continues to evolve and should be guided by a goal-directed strategy. The identification and management of patients pre-treated with anticoagulant agents continues to pose a real challenge, despite accumulating experience and awareness. The present guideline should be viewed as an educational aid to improve and standardise the care of the bleeding trauma patients across Europe and beyond. This document may also serve as a basis for local implementation. Furthermore, local quality and safety management systems need to be established to specifically assess key measures of bleeding control and outcome.

Conclusions: A multidisciplinary approach and adherence to evidence-based guidance are key to improving patient outcomes. The implementation of locally adapted treatment algorithms should strive to achieve measureable improvements in patient outcome.

Link naar het Artikel (open Acces)

    Categories

    All
    Airway Management
    Analgesia
    Bleeding
    Bloedverlies
    Brandwonden
    Cardiac Arrest
    Checklist
    CICO
    Coagulopathy
    CPR
    Cricothyrodotomy
    CRM
    Disaster Medicine
    Drugs
    ECLS
    ECMO
    ECPR
    Emergency Anesthesia
    Guideline
    Human Factors
    Hypotension
    Intubation
    Ketamine
    Military Trauma
    MTP
    Multidisciplinary
    OHCA
    Outcome
    Pediatric Resuscitation
    PHEM
    POCUS
    Prehospital
    Procedural Sedation
    Propofol
    Rapid Sequence Induction
    RCT
    Resuscitation
    Sedation
    Shock
    TBI
    Therapeutic Hypothermia
    Tranexaminezuur
    Transfusie
    Trauma
    Trauma Anesthesia
    Traumatic Brain Injury
    Trial
    TXA
    Ultrasound
    Video Laryngoscopy

    Archives

    October 2021
    August 2020
    November 2019
    October 2019
    August 2019
    January 2019
    August 2018
    July 2018
    January 2018
    December 2017
    October 2017
    September 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    September 2014
    June 2014

    RSS Feed

Anesthesiologie - Urgentiegeneeskunde
www.urgentiegeneeskunde.com



de gratis online resource over trauma-anesthesie, reanimatie, resuscitatie, airway management, prehospitale zorg en alles wat te maken heeft met de zorg voor de vitaal bedreigde patient.